Higher dose of common drug may raise hospital risk for seniors with kidney trouble
NCT ID NCT07382960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 1,100 older adults (65+) with advanced chronic kidney disease who started taking pramipexole, a drug for restless legs or Parkinson's. Researchers compared a very low starting dose (0.125 mg/day) to slightly higher doses (0.25 or 0.375 mg/day) to see if the higher doses increased the risk of hospitalization, emergency visits, or death within 30 days. The goal is to find safer prescribing practices for this vulnerable group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pramipexole
What this could lead to
If successful, this study could help doctors choose safer starting doses of pramipexole for older adults with kidney disease, reducing hospital visits.
What could go wrong
This is an observational study, not a controlled trial, so it can only show links, not cause and effect. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLDER ADULTS (65 YEARS AND OLDER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
London Health Sciences Centre Research Institute
London, Ontario, Canada